GSK/Adolor Entereg Gets Standard Review For Ileus Despite Fast Track Status
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline/Adolor’s non-opioid analgesic Entereg did not receive a priority review as requested; Adolor announced a standard review for the postoperative ileus NDA Sept. 8.